П

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

onib Hanboli	0200 0201
Estimated average burde	en
hours per response:	0.5

1. Name and Address of Reporting Ferson			2. Issuer Name <b>and</b> Ticker or Trading Symbol Eleven Biotherapeutics, Inc. [EBIO]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<u>CHANEY PAUL G</u>			<u>Energia di Biolicia pedices, inci</u> ( 1910 )	X	Director	10% Owner		
C/O ELEVEN BIOTHERAPEUTICS, INC.		CS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 05/19/2017		Officer (give title below)	Other (specify below)		
245 FIRST STREET, SUITE 1800			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) CAMBRIDGE	MA	02142		X	,			
(City)	(State)	(Zip)						

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)				6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Expiration Derivative (Month/Da Securities Acquired (A) or		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Disposed of (D) (Instr. 3, 4 and 5)				Amount			Reported Transaction(s) (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	or Number of Shares				
Stock Option	\$1.48	05/19/2017		Α		8,072		(1)	05/18/2027	Common Stock	8,072	\$ <mark>0</mark>	8,072	D	

#### Explanation of Responses:

1. The option was granted on May 19, 2017 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested.

#### Remarks:

/s/ John J. McCabe as attorney-05/23/2017

<u>in-fact</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.